scholarly article | Q13442814 |
P50 | author | Pierfranco Conte | Q56798835 |
Giulia Grisendi | Q57012601 | ||
Giulia Orsi | Q87771986 | ||
Giulia Golinelli | Q87920946 | ||
Giulia Rovesti | Q89326396 | ||
P2093 | author name string | Alessandra Recchia | |
Marco Bestagno | |||
Edwin M Horwitz | |||
Elena Veronesi | |||
Massimo Dominici | |||
Filippo Rossignoli | |||
Olivia Candini | |||
Tiziana Petrachi | |||
Francesca Miselli | |||
Carlotta Spano | |||
Benedetta Petocchi | |||
Elisabetta Manuela Foppiani | |||
Gregorio Medici | |||
Ilenia Mastrolia | |||
Massimo Pinelli | |||
P2860 | cites work | Onto better TRAILs for cancer treatment | Q26768160 |
Microtubule-binding agents: a dynamic field of cancer therapeutics | Q27690249 | ||
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells | Q28391040 | ||
c-FLIP, a master anti-apoptotic regulator | Q28391119 | ||
Albumin-bound paclitaxel: a next-generation taxane | Q29027108 | ||
Cancer statistics, 2016 | Q29547383 | ||
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo | Q30318545 | ||
Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. | Q33483354 | ||
Advances in mesenchymal stem cell-mediated gene therapy for cancer. | Q34135233 | ||
Gene therapy in pancreatic cancer | Q34302954 | ||
Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma | Q34458449 | ||
Overcoming drug resistance in pancreatic cancer. | Q35036615 | ||
Gene and cell therapy for pancreatic cancer | Q35541787 | ||
Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL. | Q36561621 | ||
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects | Q37073589 | ||
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy | Q37140126 | ||
The TRAIL apoptotic pathway in cancer onset, progression and therapy | Q37278043 | ||
Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model | Q37310677 | ||
In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. | Q37621597 | ||
nab-Paclitaxel mechanisms of action and delivery | Q38114701 | ||
Pancreatic cancer: a comprehensive review and update | Q38158783 | ||
Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells | Q38308753 | ||
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies | Q38396634 | ||
Changing the course of pancreatic cancer--Focus on recent translational advances | Q38753998 | ||
Embelin prevents LMP1-induced TRAIL resistance via inhibition of XIAP in nasopharyngeal carcinoma cells | Q38763961 | ||
Tumor Stroma Manipulation By MSC. | Q38764997 | ||
Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells. | Q38785499 | ||
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis | Q38829982 | ||
Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer | Q38840234 | ||
Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer | Q38850605 | ||
Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells | Q38918317 | ||
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas | Q38938230 | ||
Surrounding pancreatic adenocarcinoma by killer mesenchymal stromal/stem cells. | Q38993056 | ||
Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice | Q39028542 | ||
Adipose tissue-derived stromal cells primed in vitro with paclitaxel acquire anti-tumor activity | Q39094393 | ||
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells | Q39319003 | ||
Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells | Q39649739 | ||
Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis | Q39653516 | ||
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells | Q39765503 | ||
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. | Q39852557 | ||
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway | Q41205677 | ||
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. | Q41501622 | ||
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy | Q43100976 | ||
TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells | Q44226747 | ||
The future of mesenchymal stem cell-based therapeutic approaches for cancer - From cells to ghosts | Q45875024 | ||
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells | Q57243535 | ||
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer | Q61797115 | ||
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL | Q71046859 | ||
Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C | Q73895525 | ||
Pancreatic cancer | Q87198210 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | paclitaxel | Q423762 |
pancreatic adenocarcinoma | Q18556189 | ||
P304 | page(s) | 436-448 | |
P577 | publication date | 2019-01-01 | |
P1433 | published in | Theranostics | Q21051383 |
P1476 | title | MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma | |
P478 | volume | 9 |